Clinical Guideline: Management of Urinary Retention

DRAFT ONLY – NOT FOR CLINICAL USAGE UNTIL REVIEWED

1. Initial Assessment & Documentation

Full vital signs (HR, BP, temperature, sepsis screen)

Abdominal examination for palpable distended bladder

Digital Rectal Examination (DRE) in males to assess:

• Prostate size

• Prostate tenderness

• Rectal tone

Focused neurological examination:

• Saddle sensation

• Lower limb power/reflexes

• Anal tone

 

Accurate documentation is essential for determining the underlying pathology and subsequent management plan.

• Symptom Presentation:

  • Painful: Usually indicates Acute Urinary Retention. The patient is typically in significant distress.

  • Painless: Suggests Chronic or Acute-on-Chronic Retention, where the bladder has gradually distended over time.

• Volume Metrics:

  • Document the volume on bladder scan prior to catheterisation.

  • Document the initial volume drained immediately following catheter insertion. Note if there are clots/haematuria.

 

Recommended baseline investigations:

• Urinalysis ± urine culture

• Urea, creatinine, electrolytes

• Bladder scan (if available)

Renal imaging should be considered if:

• Renal impairment is present

• Chronic retention suspected

• Hydronephrosis suspected

PSA testing is not recommended in ED as it may be falsely elevated during acute retention or catheterisation.

2. Red Flags (Urgent Intervention Required)

The presence of any of the following requires immediate hospital admission and specialist involvement.

High-Pressure Urinary Retention / Hydronephrosis

• Signs: Associated with Acute Renal Failure (elevated Creatinine/low eGFR), there may be a large amount (eg > 1.5 litres on initially draining the bladder)

High-Pressure Chronic Retention is defined not only by volume but by evidence of upper urinary tract obstruction, including:

• Hydronephrosis on ultrasound/KUB CT

• Elevated creatinine / renal impairment

• Large painless bladder volume (>800–1000 mL)

• These patients are at risk of renal failure and post-obstructive diuresis.

• This is an absolute contraindication for a Trial of Void (TOV). DO NOT refer these patients for TOV.

• Management:

  • Admit for inpatient monitoring.

  • Monitor for Post-Obstructive Diuresis (massive urine output post-decompression).

  • Perform hourly urine measurements.

  • Monitor for hypokalaemia and electrolyte imbalances; IV fluid replacement may be required.

In a regional ED setting:

If initial drainage exceeds 1000 mL, the patient should remain in ED for at least 4–6 hours observation to monitor for:

• Hypotension

• Post-obstructive diuresis

• Electrolyte abnormalities

Post-Obstructive Diuresis is defined as:

• >200 mL/hour for 2 consecutive hours, or

• >3 L urine output in 24 hours

Patients with POD require hospital admission under the General Surgical team for:

• Strict fluid balance monitoring

• Electrolyte monitoring

• Possible mL-for-mL IV fluid replacement

 

 

Cauda Equina Syndrome / Spinal Cord Compression

• Signs: New bladder/bowel dysfunction, saddle anaesthesia, and decreased lower limb strength. AND Anal sphincter tone

• Emergency: Especially if the patient has a history of metastatic prostate cancer. This is an oncological emergency. Failure to treat immediately risks permanent spinal cord injury. Steroids/MRI/Urgent Referral to Oncology/Radiotherapy may be needed.

 

Additional red flags requiring urgent senior ED review and surgical consultation:

• Urosepsis

• Gross haematuria with clot retention

• Suspected urethral injury

• Acute neurological deficit

• Traumatic catheterisation

Do NOT attempt urethral catheterisation if urethral injury suspected.

Clinical indicators include:

• Blood at urethral meatus

• Pelvic fracture

• Perineal bruising

• High-riding prostate on DRE

Urgent surgical/urology consultation and possible suprapubic catheterisation may be required.

 

3. Simple Management (Low-Risk Patients)

Applicable for stable males with normal renal function and no "red flags."

Recommended first-line catheter:

16–18 Fr Foley catheter

This is adequate for most cases of acute urinary retention.

-If catheterisation fails:

Stepwise escalation:

1. Coude-tip catheter

2. Larger catheter (18–20 Fr)

3. Senior clinician attempt

-After two failed attempts, stop further attempts and consult the General Surgical team.

 

-If haematuria or clots are present:

Use:

20–22 Fr three-way catheter

 

-Urinary tract infection should be screened for in all patients.

• Send Mid-Stream Urine (MSU) for culture

• If febrile or dipstick positive, initiate appropriate antibiotics

-Retention with infection ("dirty retention") may require admission or close follow-up.

 

 

 

A. Address Reversible Factors

• Treat underlying constipation (a common precipitant of retention).

-Other common ED causes include:

• Medications

• Urinary infection

• Post-operative retention

• Alcohol intoxication

• Neurological disease

• Urethral stricture

• Female urinary retention

 

-Document recent medications and precipitating factors, particularly:

• Anticholinergic medications

• Antihistamines

• Opioids

• Tricyclic antidepressants

• Sympathomimetics

• Calcium channel blockers

• Recent general or spinal anaesthesia

• Alcohol intoxication

• Severe constipation

-Medication-induced urinary retention is frequently encountered in regional ED settings, especially among elderly patients.

 

B. Pharmacotherapy (BPH Management)

If the patient is not already on treatment for Benign Prostatic Hyperplasia (BPH), consider management options such as alpha blockers or combination therapies.

-Patients should be commenced on an alpha-blocker at time of catheterisation.

Recommended medication:

Tamsulosin 400 micrograms daily

Evidence shows this significantly improves Trial Of Void (TOV) success rates.

Patients should ideally receive alpha-blocker therapy for at least 48–72 hours before TOV.

 

Medication Type

Examples

Patient Education

Alpha Blocker

Tamsulosin, Silodosin

Warn of postural hypotension (dizziness on standing) in the first 24–48 hours. Advise caution when rising at night.

Combination Therapy

Medications containing Tamsulosin and Dutasteride (Duodart or Doubluts)

Carries similar postural risks. Note that Dutasteride may cause decreased libido or erectile dysfunction as potential side effects.

C. Catheter Education

• Provide a pre-prepared Catheter Pack.

• Educate the patient on:

  • Leg bag management and hygiene.

  • Connecting a larger drainage bag at night.

  • Emptying and cleaning protocols.

D. Referral for Trial of Void (TOV)

Follow MBPH TOV policy

TOV should typically be attempted 48–72 hours after catheterisation, while continuing alpha-blocker therapy.

The guideline should specify Fail TOV management.

If TOV fails in outpatient clinic:

• Patient should be re-catheterised

• Referred to Urology clinic for further evaluation

• Consideration of elective TURP or definitive management

Patients should not be routinely referred back to ED unless:

• Severe symptoms

• Renal failure

• Sepsis

• Catheter complications

 

When referring the patient for a TOV (per hospital policy), the following data must be documented:

1. Retention Type: Painful vs. Painless.

2. Volume Data: Pre-insertion scan volume AND initial volume drained.

3. Renal Function: Current eGFR.

4. Imaging/Labs: PSA (if available), Renal Tract Ultrasound, or CT Abdomen/Pelvis results.

Special Patient Groups

Urinary retention in females is uncommon and warrants further evaluation.

Possible causes include:

• Neurological disease

• Pelvic organ prolapses

• Urethral stricture

• Post-operative complications

These patients require urology follow-up.

 

In hospitals without inpatient urology:

The General Surgical team should be consulted for:

• Difficult catheterisation

• Suspected urethral injury

• Post-obstructive diuresis requiring admission

• Consideration of suprapubic catheterisation